India-based CRO GVK Biosciences has entered into a collaboration agreement with U.S.-based Endo Pharmaceuticals, focusing on discovering novel small molecules targeting an exciting protein.
GVK BIO will deliver a clinical candidate and Endo will develop and commercialize the product. The collaboration arose out of a newly launched concept at GVK BIO, Early Discovery Assets (EDATM). GVK Biosciences is building a portfolio of discovery project assets for potential early-stage partnering, focused around pain and inflammation. GVK Biosciences develops these assets to a stage of demonstrated value and then looks to partner and co-develop them with life science companies.